Global Pharmatech Inc 的盈利质量评分为 B+/50.591217。该评分基于盈利能力、增长、现金生成与资本分配以及杠杆四个维度。
Global Pharmatech Inc 何时发布财报?
Global Pharmatech Inc 的下一份财报预计在 发布
Global Pharmatech Inc 的预期收益是多少?
根据华尔街分析师的预测,Global Pharmatech Inc 的预期收益为 $
Global Pharmatech Inc 是否超出收益预期?
Global Pharmatech Inc 最近的收益为 $, 预期。
关键数据
前收盘价
$0.08
开盘价
--
当日区间
-
52周范围
-
交易量
--
平均成交量
--
股息收益率
--
每股收益(TTM)
--
市值
--
什么是 GBLP?
Global Pharmatech, Inc. engages in the discovery, development, manufacturing, and marketing of proprietary drugs developed based on traditional Chinese medicine. The company is headquartered in Changchun, Jilin and currently employs 217 full-time employees. The company went IPO on 2006-05-12. The Company’s main patented products include JUTAI SOFT CAPSULE, QINGXUAN ANTI-HYPERTENSION TABLET, YANREQING TABLET. The firm is also engaged in the manufacture and sales of other proprietary drugs, generics and dietary supplements used to treat symptoms ranging from headaches, coughing and dry mouth to infections and numbness of limbs. The firm also engages in the provision of biotechnology services, including research and development, testing, manufacturing drugs in liquid and solid dose forms, sales and marketing. The firm conducts its business in the domestic and overseas markets.